This trial tests a new cancer drug, to see if it is safe and effective, in people with a certain type of lung cancer who have no other treatment options.
1 Primary · 5 Secondary · Reporting Duration: Up to approximately 9 months
Experimental Treatment
125 Total Participants · 2 Treatment Groups
Primary Treatment: Pemigatinib · No Placebo Group · Phase 2
Age 18 - 99 · All Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: